Assenagon Asset Management S.A. purchased a new position in shares of STAAR Surgical (NASDAQ:STAA – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 211,387 shares of the medical instruments supplier’s stock, valued at approximately $13,518,000. Assenagon Asset Management S.A. owned approximately 0.44% of STAAR Surgical as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Assetmark Inc. grew its stake in shares of STAAR Surgical by 42.1% during the 4th quarter. Assetmark Inc. now owns 645 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 191 shares in the last quarter. Lazard Asset Management LLC increased its holdings in STAAR Surgical by 131.1% during the first quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 388 shares during the last quarter. UBS Group AG increased its holdings in STAAR Surgical by 130.7% during the second quarter. UBS Group AG now owns 805 shares of the medical instruments supplier’s stock worth $57,000 after buying an additional 456 shares during the last quarter. Captrust Financial Advisors increased its holdings in STAAR Surgical by 348.4% during the second quarter. Captrust Financial Advisors now owns 825 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 641 shares during the last quarter. Finally, Money Concepts Capital Corp increased its holdings in STAAR Surgical by 125.0% during the fourth quarter. Money Concepts Capital Corp now owns 1,251 shares of the medical instruments supplier’s stock worth $61,000 after buying an additional 695 shares during the last quarter. 96.70% of the stock is owned by institutional investors.
STAAR Surgical Stock Performance
STAA stock opened at $52.57 on Friday. The company’s 50-day simple moving average is $59.33 and its 200 day simple moving average is $61.84. STAAR Surgical has a 52 week low of $46.35 and a 52 week high of $112.27. The company has a market capitalization of $2.54 billion, a PE ratio of 82.14 and a beta of 1.18.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the stock. Piper Sandler assumed coverage on shares of STAAR Surgical in a report on Monday, April 17th. They set a “neutral” rating and a $65.00 target price on the stock. StockNews.com assumed coverage on shares of STAAR Surgical in a report on Thursday, May 18th. They set a “hold” rating on the stock. William Blair downgraded shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 7th. Stifel Nicolaus lowered their target price on shares of STAAR Surgical from $60.00 to $55.00 in a report on Monday, June 12th. Finally, Needham & Company LLC upped their price objective on shares of STAAR Surgical from $78.00 to $84.00 in a report on Thursday, May 4th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.73.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Further Reading
- Five stocks we like better than STAAR Surgical
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
- SMART Global Holdings Momentum, Room To Move Higher?
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
